Analysts Set Envista Holdings Co. (NYSE:NVST) PT at $20.13

Envista Holdings Co. (NYSE:NVST) has earned an average rating of “Hold” from the fifteen brokerages that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and three have issued a buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $20.13.

A number of equities research analysts recently issued reports on the company. Jefferies Financial Group raised their price target on Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a research note on Thursday. Leerink Partners upgraded Envista from an “underperform” rating to a “market perform” rating and lifted their target price for the stock from $16.00 to $23.00 in a research report on Thursday, October 31st. Robert W. Baird boosted their target price on shares of Envista from $17.00 to $22.00 and gave the company a “neutral” rating in a research note on Thursday, October 31st. Leerink Partnrs raised shares of Envista from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 31st. Finally, Stifel Nicolaus boosted their price objective on shares of Envista from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd.

Hedge Funds Weigh In On Envista

Institutional investors have recently modified their holdings of the stock. Ariel Investments LLC lifted its position in shares of Envista by 11.0% during the 2nd quarter. Ariel Investments LLC now owns 9,871,152 shares of the company’s stock valued at $164,157,000 after buying an additional 978,952 shares in the last quarter. Nuance Investments LLC lifted its holdings in Envista by 4.4% during the third quarter. Nuance Investments LLC now owns 7,346,534 shares of the company’s stock valued at $145,168,000 after purchasing an additional 308,221 shares in the last quarter. Clarkston Capital Partners LLC increased its stake in shares of Envista by 0.4% during the third quarter. Clarkston Capital Partners LLC now owns 4,347,300 shares of the company’s stock worth $85,903,000 after purchasing an additional 17,085 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Envista by 26.5% during the 3rd quarter. Franklin Resources Inc. now owns 3,971,662 shares of the company’s stock worth $78,480,000 after purchasing an additional 830,861 shares during the last quarter. Finally, Pacer Advisors Inc. lifted its stake in Envista by 22.2% in the 3rd quarter. Pacer Advisors Inc. now owns 3,529,827 shares of the company’s stock valued at $69,749,000 after buying an additional 642,401 shares in the last quarter.

Envista Trading Up 0.7 %

NVST stock opened at $21.44 on Friday. The firm’s fifty day simple moving average is $20.03 and its two-hundred day simple moving average is $18.85. The stock has a market capitalization of $3.69 billion, a price-to-earnings ratio of -2.76, a price-to-earnings-growth ratio of 1.88 and a beta of 1.33. The company has a quick ratio of 1.77, a current ratio of 2.08 and a debt-to-equity ratio of 0.42. Envista has a twelve month low of $15.15 and a twelve month high of $24.79.

Envista (NYSE:NVST) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of $0.09 by $0.03. The company had revenue of $601.00 million for the quarter, compared to the consensus estimate of $590.34 million. Envista had a negative net margin of 53.42% and a positive return on equity of 3.76%. The firm’s revenue was down 4.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.43 EPS. As a group, analysts anticipate that Envista will post 0.72 earnings per share for the current year.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.